Developing A First-In-Class Regenerative Therapy for Diabetes
Our goal is to identify, characterize and optimize small molecules that stimulate beta-cell regeneration.
Our principle experimental strategy is to develop and utilize high throughput screening platforms to uncover therapeutic leads, utilize in vitro and in vivo models to develop in depth mechanistic understanding of lead compound function and to deploy medicinal chemistry efforts to optimize lead compounds for in vivo use, i.e. develop new medicines for diabetes!
Lead Compound Discovery
High-Throughput, High-Content Screening
Pancreatic islets are isolated, plated and compound-treated to identify molecules that stimulate beat-cell replication. Automated image aquisition and analysis (Cellomics ArrayScan) are utilized to maximize throughput and eliminate bias.
Lead Compound Confirmation
Lead Compound Characterization
Lead Compound Optimization
A major goal of the Annes Lab is to bridge the space between lead compound discovery and the development of drug-like compound series
Using computational structure-based modeling, lead compounds are stragegically derivatized for SAR, target ID studies and compound optimization (potency, efficacy, specificity, pharmacokinetics and tolerability).
Dr. Annes is a Stanford ChEM-H Fellow.